Last reviewed · How we verify
Risperidal Consta
At a glance
| Generic name | Risperidal Consta |
|---|---|
| Also known as | Risperidone long-acting injection |
| Sponsor | Réseau de Santé Vitalité Health Network |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia (PHASE4)
- Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
- Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia (PHASE1)
- Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia (PHASE4)
- Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia (PHASE3)
- Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder (PHASE4)
- Aripiprazole, Abilify Maintena Collaborative Clinical Protocol (PHASE4)
- Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risperidal Consta CI brief — competitive landscape report
- Risperidal Consta updates RSS · CI watch RSS
- Réseau de Santé Vitalité Health Network portfolio CI